A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2017; you can also visit the original URL.
The file type is
S54 3rd ESTRO Forum 2015 passing rate for target volumes was found to be above 96% for a 3%/3mm criteria. Differences in tumor control probability were within 2.5% for liver and breast, however, for head-and-neck and prostate patients the differences were up to 6.5% and up to 11% for lung patients. We conclude that approximations introduced in analytical dose calculation methods can result in significant range uncertainties for heterogeneous patient geometries or introduce a systematicallydoi:10.1016/s0167-8140(15)40111-2 fatcat:6d3etpasn5ecjaivlrkngwezl4